Editorial Board

A. Seth  
Editor-in-Chief  
Laboratory of Molecular Pathology, Sunnybrook and Women’s CHSC,  
Toronto, ON, Canada

J.G. Delinassios  
Managing Editor and Executive Publisher,  
International Institute of Anticancer Research, Athens, Greece

L.A. Aaltonen  
Department of Medical Genetics, University of Helsinki, Finland

S. Aaronson  
Deryal H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, USA

J.D. Aitchison  
Institute for Systems Biology, Seattle, WA, USA

W. Anorge  
IAET, Borex, Switzerland

S. Antonarakis  
Division of Medical Genetics, University of Geneva Medical School, Switzerland

F.G. Barr  
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

A.M. Chinnaiyan  
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA

B.F.C. Clark  
Department of Molecular Biology, University of Aarhus, Denmark

R. Clarke  
Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA

I. Dunham  
The Wellcome Trust Sanger Centre, Wellcome Trust Genome Campus, Cambridge, UK

N.A. Ellis  
Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

J.A. Fernandes-Pol  
Metalloproteomics, LLC, Chesterfield, MO, USA

C.V. Forst  
McClintock Resource, Bioscience Division, Los Alamos National Laboratory, NM, USA

M. Fountoulakis  
F. Hoffman - La Roche Pharmaceutical Research, Basel, Switzerland

W.L. Gerald  
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

J.W. Gray  
Cancer Genetics Program, Comprehensive Cancer Center, University of California San Francisco, CA, USA

B.B. Haab  
van Andel Research Institute, Grand Rapids, MI, USA

J.D. Hoheisel  
Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany

R.P. Huang  
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA

T.H.M. Huang  
Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA

Yasumasa Ito  
Orthopedic Division, National Cancer Center Hospital, Tokyo, Japan

Yoshiaki Ito  
Institute of Molecular and Cell Biology, Clinical Research Centre, Singapore

V.C. Jordan  
Diana, Princess of Wales Cancer Research Department, Lynn Sage Breast Cancer Research Program, Northwestern University Medical School, Chicago, IL, USA

A. Kallioniemi  
Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland

O.P. Kallioniemi  
Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland

M. Kanehisa  
Bioinformatics Center, Institute for Chemical Research, Kyoto University, Japan

S.E. Kern  
Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA

K. Khalili  
College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA

S.D. Kottridis  
Department of Virology, Hellenic Anticancer Institute, Athens, Greece

P. Lichter  
Deutsches Krebsforschungszentrum, Heidelberg, Germany

G. Lubeck  
Department of Pediatrics, University of Vienna, Austria

P.J. McCormick  
Center for Comp. Functional Genomics, VA Medical Center University at Albany, SUNY, Rensselaer, NY, USA

J.D. Minna  
Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA

F. Mitelman  
Department of Clinical Genetics, University Hospital, Lund, Sweden

P. Nelson  
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 2, 2005.

AACR-Cancer Research Foundation, U.S.A.
Association de la Recherche contre le Cancer, France
Association Nationale de la Recherche Technique, France
Austrian Embassy Development Cooperation, Addis Ababa, Ethiopia
Berliner Krebsgesellschaft e.V., Berlin, Germany
Cancer Society, Stockholm, Sweden
Centre of Excellence in Molecular Medicine MolMed, European Commission
Crafoord Foundation, Sweden
Department of Defense, U.S.A.
DVA Medical Center, U.S.A.
Elsa Pardee Foundation, U.S.A.
European Union
Felleslegatet til Fordel
Fondo de Investigación Sanitaria, Spain
G. Nilsson Cancer Foundation, Sweden
German Academic Exchange Service
German Ministry of Education and Science
Hospital Privado de Comunidad, Mar del Plata, Argentina
Ireland's Higher Educational Authority Program
Korea Ministry of Science and Technology
Medical Research Council, U.K.
Metalloproteomics LLC, Chesterfield, MO, U.S.A.
Ministère des Finances et de l’Industrie, France
Misses Barrie Charitable Trust, U.K.
National Cancer Institute, U.S.A.
National Office for Research and Technology, Hungary
National Science Council, Taiwan, R.O.C.
Norwegian Research Council
Oligene GmbH, Berlin, Germany
Roswell Park Alliance Foundation, U.S.A.
The King Gustav V Jubilee Fund, Stockholm, Sweden
The Ralph C. Wilson Sr. and Ralph C. Wilson Jr. Medical Research Foundation, U.S.A.
The Swedish Cancer Society
UICC International Cancer Technology Transfer Fellowship
Contents, Volume 2, 2005

Number 1

Genomics, Proteomics and Cancer: Specific Ribosomal, Mitochondrial, and Tumor Reactive Proteins can be Used as Biomarkers for Early Detection of Breast Cancer in Serum. J. ALBERTO FERNANDEZ-POL, PAUL D. HAMILTON, DENNIS J. KLOS (Chesterfield, MO, U.S.A.)............................................................ 1


* Protein Microarrays – A Promising Tool for Cancer Diagnosis. N. SCHNEIDERHAN-MARRA, A. KIRN, A. DÖTTINGER, M. TEMPLIN, G. SAUER, H. DEISSLER, T.O. JOOS (Ulm; Reutlingen, Germany)..... 37

Detection of Specific mRNAs in Culture Medium Conditioned by Human Tumour Cells: Potential for New Class of Cancer Biomarkers in Serum. L. O’DRISCOLL, E. KENNY, M. PEREZ DE VILLARREAL, M. CLYNES (Dublin, Ireland)............................................................................................................... ................ 43


Number 2


* A Functional Genomic Approach for Screening Preneoplastic Stages of Sporadic Colon Cancer. F.E. AHMED (Greenville, NC, U.S.A.)....................................................................................................................... 71


Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. H. ZHANG, Y. DONG, H. ZHAO, J.D. BROOKS, L. HAWTHORN, N. NOWAK, J.R. MARSHALL, A.C. GAO, C. IP (Buffalo, NY; Stanford, CA, U.S.A.)........................................................................................................... 97

Molecular Determinants of Response of Tumor Cells to Berberine. T. EFFERTH, Z. CHEN, B. KAINA, GAN WANG (Heidelberg; Mainz, Germany; Guangzhou, P.R. China; Detroit, MI, U.S.A.) ......................................................................................... 115

Number 3

Immune Signature of Malignant Pleural Mesothelioma as Assessed by Transcriptome Analysis. S. MOHR, A. NEUVILLE, M.C. BOTTIN, J.C. MICILLINO, G. KEITH, B.H. RIHN (Strasbourg; Nancy, France) . . .... 125

Down-regulation of BRMS1 mRNA Expression in Breast Cancer is not Related to the Presence of Axillary Node Metastasis. F. GÓMEZ-ESQUER, D. AGUDO, F. MARTÍNEZ-ARRIBAS, G. DÍAZ-GIL, M. POLLÁN, J. SCHNEIDER (Madrid, Spain) .......................................................... 145


Abstracts of the First International Conference of the Hellenic Proteomics Society .................. 159

Proteomic Analysis of Membrane-associated Proteins from the Breast Cancer Cell Line MCF7. C. PIONNEAU, L. CANELLE, J. BOUSQUET, J. HARDOUNI, J. BIGEARD, M. CARON, R. JOUBERT-CARON (Bobigny; Marcy l’Etoile, France).......................... 199

Specific Expression of Potential Tumour Marker Proteins, Similar to No On or Off Transient A and HIRA-interacting Protein 5, in Mouse N1E-115 Neuroblastoma Cell Line. J.-E. OH, E. ENGIDAWORK, J.-H. SHIN, G. LUBEC (Vienna, Austria; Addis Ababa, Ethiopia) .......................................................... 209

Biomarkers for Sensitivity to Docetaxel and Paclitaxel in Human Tumor Cell Lines In Vitro. E. IZBICKA, D. CAMPOS, G. CARRIZALES, A. TOLCHER (San Antonio, TX, U.S.A.) .......................................................... 219

* Stathmin in Cell Proliferation and Cancer Progression. G.V. SHERBET, F. CAJONE (Newcastle-upon-Tyne, U.K.; Huntington Beach, CA, U.S.A.; Milan, Italy) .......................................................... 227

The Cell Cycle Regulators P16INK4a, P15INK4b and Cyclin D1: Relationship to Clinicopathological Parameters and Disease-free Survival in Laryngeal Carcinoma Patients. E. EL-SALAHY, A.H. ABOU-GHALIA, A. ADLI, S.K. KASSIM (Cairo, Egypt) .......................................................... 239

* Tumor Suppressor Genes on Human Chromosome 3 and Cancer Pathogenesis. S. INGVARSSON (Reykjavik, Iceland) .......................................................... 247

Application of Microarrays for the Prediction of Therapy Response in Breast Cancer. B. GYŐRFFY, P. SUROWIAK, H. LAGE (Berlin, Germany; Budapest, Hungary; Wroclaw, Poland) .......................................................... 255


The Protein Profile of the Human Immature T-cell Line CCRF-CEM. A.K. ANAGNOSTOPOULOS, K. VOUGAS, A. KOLIALEXI, A. MAVROU, M. FOUNTOULAKIS, G.T. TSANGARIS (Athens, Greece) .......................................................... 271

* Phylogenetics: Applications, Software and Challenges. A. STAMATAKIS (Heraklion, Greece) .......................................................... 301
Number 6


* Quantitative Real-time RT-PCR: Application to Carcinogenesis. F.E. AHMED (Greenville, NC, U.S.A.) ........ 317


Proteomic Analysis of a Human Prostate Cancer Cell Line after Incubation with a Novel Somatostatin14 Derivative. Z. LIU, M. MARQUEZ, S. NILSSON, A.R. HOLMBERG, A. ALAIYA (Stockholm, Sweden; Jinan, China) ................................................................. 347


Volume 2, 2005, Index .......................................................................................................................... 365-380

Reviews (pages 37, 71, 137, 227, 247, 255, 301, 317)
Subject Index
(Figures refer to page numbers)

ABC transporters, berberine, cluster analysis, DNA repair, microarray analysis, multidrug resistance, 115
Adherent properties, endothelial cells, VEGF, 265
Androgen receptor, selenium, chemoprevention, prostate carcinogenesis, 97
Animal models, cancer genes, prostate cancer, comparative genomics, review, 137
Antibody microarrays, mass spectrometry, protein profiling, matrix-assisted laser desorption, ionization time of flight mass spectrometry, 353
Apoptosis, p53, microarray, protein, mRNA, 61
Berberine, ABC transporters, cluster analysis, DNA repair, microarray analysis, multidrug resistance, 115
Biomarker, docetaxel, paclitaxel, cancer, Bel-2, 219
Biomarker, MALDI mass spectrometry, proteomics, tissue profiling, soft tissue sarcoma, 333
Biomarker, neuroblastoma cell line, no on or off transient A, HIRA-interacting protein 5, proteomics, 209
Biomarker, proteomics, membrane proteins, breast cancer, 199
Biomarkers, breast cancer, metallopanstimulin, 1
Biomarkers, secreted mRNA, cancer, conditioned medium, serum/plasma, genomic profile, reverse transcriptase-polymerase chain reaction, 43
BRCA1, breast cancer, hypoxia, HRE, microarray, 83
Breast cancer, biomarker, proteomics, membrane proteins, 199
Breast cancer, BRCA1, hypoxia, HRE, microarray, 83
Breast cancer, cDNA microarrays, drug resistance, differential gene expression, response prediction, review, 255
Breast cancer, metallopanstimulin, biomarkers, 1
Breast cancer, metastasis, BRMS1, 145
Breast cancer, protein microarray, bead-based technology, sandwich immunoassays, review, 37
Breast carcinoma, metallopanstimulin, ribosomal protein S27, zinc finger proteins, 53
BRMS1, cancer, breast, metastasis, 145
Cancer genes, prostate cancer, comparative genomics, animal models, review, 137
Cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
Cell cycle regulation, cancer progression, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
Cell motility, cancer progression, cell cycle regulation, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
Cell proliferation, cancer progression, cell cycle regulation, cell motility, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
Chromosomal instability, tumor suppressor gene, chromosome 3, FHIT, chromosome instability, mutation, FRA3B, VHL, elimination test, review, 247
Chemoprevention, selenium, prostate carcinogenesis, androgen receptor, 97
Chromosome 3, tumor suppressor gene, FHIT, chromosome instability, mutation, FRA3B, VHL, CER1, elimination test, review, 247
Comparative genomic hybridization, head and neck squamous cell carcinoma, genomic instability, genomic instability index, oral cavity, eosinophilic index, fluorescence in situ hybridization, eosinophilic infiltrate, 307
Comparative genomics, cancer genes, prostate cancer, animal models, review, 137
Conditioned medium, secreted mRNA, cancer, serum/plasma, genomic profile, biomarkers, reverse transcriptase-polymerase chain reaction, 43
Cyclin D1, laryngeal carcinoma, disease-free survival, p16INK4a, p15INK4b, 239
Detection chemistry, colorectal cancer, gene expression, LCM, real-time PCR, review, 317
Diagnosis, colorectal cancer, gene expression, microarrays, regulation, PCR, review, 71
Comparative genomic hybridization, head and neck squamous cell carcinoma, genomic instability, genomic instability index, oral cavity, eosinophilic index, fluorescence in situ hybridization, eosinophilic infiltrate, 307
Comparative genomics, cancer genes, prostate cancer, animal models, review, 137
Conditioned medium, secreted mRNA, cancer, serum/plasma, genomic profile, biomarkers, reverse transcriptase-polymerase chain reaction, 43
Cyclin D1, laryngeal carcinoma, disease-free survival, p16INK4a, p15INK4b, 239
Detection chemistry, colorectal cancer, gene expression, LCM, real-time PCR, review, 317
Diagnosis, colorectal cancer, gene expression, microarrays, regulation, PCR, review, 71
Differential gene expression, breast cancer, cDNA microarrays, drug resistance, response prediction, review, 255
Disease-free survival, laryngeal carcinoma, p16INK4a, p15INK4b, cyclin D1, 239
DNA repair, ABC transporters, berberine, cluster analysis, microarray analysis, multidrug resistance, 115
Head and neck squamous cell carcinoma, genomic instability, growth factors, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227

HIRA-interacting protein 5, neuroblastoma cell line, no on or off transient A, proteomics, biomarker, review, 209

HRE, BRCA1, breast cancer, hypoxia, microarray, 83

Hypoxia, BRCA1, breast cancer, HRE, microarray, 83

Immunoresistance, mesothelioma, microarray, transcriptomics, lymphocyte, 125

Invasion, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227

Ionization time of flight mass spectrometry, antibody microarrays, mass spectrometry, protein profiling, matrix-assisted laser desorption, 353

Laryngeal carcinoma, disease-free survival, p16INK4a, p15INK4b, cyclin D1, 239

LCM, colorectal cancer, detection chemistry, gene expression, real-time PCR, review, 317

LNCAp cell line, proteomic analysis, somatostatin, 347

Lymphocyte, immunoresistance, mesothelioma, microarray, transcriptomics, 125

MALDI mass spectrometry, proteomics, tissue profiling, biomarker, soft tissue sarcoma, 333

MALDI-MS, human, T-cell, CCRF-CEM, proteomics, two-dimensional protein database, mass spectrometry, 271

Mass spectrometry, antibody microarrays, protein profiling, matrix-assisted laser desorption, ionization time of flight mass spectrometry, 353

Mass spectrometry, human, T-cell, CCRF-CEM, proteomics, two-dimensional protein database, MALDI-MS, 271

Matrix-assisted laser desorption, antibody microarrays, mass spectrometry, protein profiling, ionization time of flight mass spectrometry, 353

Membrane proteins, biomarker, proteomics, breast cancer, 199

Mesothelioma, immunoresistance, microarray, transcriptomics, lymphocyte, 125

Metallopanstimulin, breast cancer, biomarkers, 1

Metallopanstimulin, breast carcinoma, ribosomal protein S27, zinc finger proteins, 53

Metastasis, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227

Metastasis, cancer, breast, BRMS1, 145

Microarray analysis, ABC transporters, berberine, cluster analysis, DNA repair, multidrug resistance, 115

Microarray, BRCA1, breast cancer, hypoxia, HRE, 83

Microarray, immunoresistance, mesothelioma, transcriptomics, lymphocyte, 125
Proteomics, biomarker, membrane proteins, breast cancer, Proteomic analysis, LNCaP cell-line, somatostatin, mRNA, p53, apoptosis, microarray, Protein, p53, apoptosis, microarray, mRNA, Protein profiling, antibody microarrays, mass spectrometry, Protein microarray, bead-based technology, sandwich

Prostate carcinogenesis, selenium, chemoprevention, androgen receptor, 199

Proteomics, human, T-cell, CCRF-CEM, two-dimensional protein database, mass spectrometry, MALDI-MS, 271

Proteomics, MALDI mass spectrometry, tissue profiling, biomarker, soft tissue sarcoma, 333

Proteomics, neuroblastoma cell line, no on or off transient A, HIRA-interacting protein 5, biomarker, 209

Proteomics, transitional cell carcinoma, 151

RAxML, phylogenetic interference, phylogenetic software, review, 301

Real-time PCR, colorectal cancer, detection chemistry, gene expression, LCM, review, 317

Redox modification, thiol-proteomics, selenium anticancer action, 25

Regulation, colorectal cancer, diagnosis, gene expression, microarrays, PCR, review, 71

Response prediction, breast cancer, cDNA microarrays, drug resistance, differential gene expression, review, 255

Reverse transcriptase-polymerase chain reaction, secreted mRNA, cancer, conditioned medium, serum/plasma, genomic profile, biomarkers, 43

Review, breast cancer, cDNA microarrays, drug resistance, differential gene expression, response prediction, 255

Review, cancer genes, prostate cancer, comparative genomics, animal models, 137

Review, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227

Oral cavity, head and neck squamous cell carcinoma, genomic instability, genomic instability index, comparative genomic hybridization, eosinophilic index, fluorescence in situ hybridization, eosinophilic infiltrate, 307

P15INK4a, laryngeal carcinoma, disease-free survival, p16INK4a, cyclin D1, 239
P16INK4a, laryngeal carcinoma, disease-free survival, p15INK4a, cyclin D1, 239
P53, apoptosis, microarray, protein, mRNA, 61
Paclitaxel, docetaxel, cancer, biomarker, Bel-2, 219
PCR, colorectal cancer, diagnosis, gene expression, microarrays, regulation, review, 71
Phylogenetic interference, RAxML, phylogenetic software, review, 301
Phylogenetic software, phylogenetic interference, RAxML, review, 301

Prognosis, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
Prostate cancer, cancer genes, comparative genomics, animal models, review, 137
Prostate carcinogenesis, selenium, chemoprevention, androgen receptor, 97

Protein microarray, bead-based technology, sandwich immunoassays, breast cancer, review, 37

Protein profiling, antibody microarrays, mass spectrometry, matrix-assisted laser desorption, ionization time of flight mass spectrometry, 353

Protein, p53, apoptosis, microarray, mRNA, 61

Proteomic analysis, LNCaP cell-line, somatostatin, 347

Proteomics, biomarker, membrane proteins, breast cancer, 199

CANCER GENOMICS & PROTEOMICS 2: (2005)

S100A4, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, signal transduction, suppressor genes, tumour promoter genes, review, 227

Sandwich immunoassays, protein microarray, bead-based technology, breast cancer, review, 37

Secreted mRNA, cancer, conditioned medium, serum/plasma, genomic profile, biomarkers, reverse transcriptase-polymerase chain reaction, 43

Selenium anticancer action, thiol-proteomics, redox modification, 25

Selenium, chemoprevention, prostate carcinogenesis, androgen receptor, 97

375
Serum/plasma, secreted mRNA, cancer, conditioned medium, genomic profile, biomarkers, reverse transcriptase-polymerase chain reaction, 43

Signal transduction, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, suppressor genes, tumour promoter genes, review, 227

Soft tissue sarcoma, MALDI mass spectrometry, proteomics, tissue profiling, biomarker, 333

Somatostatin, proteomic analysis, LNCaP cell line, 347

Suppressor genes, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, tumour promoter genes, review, 227

T-cell, human, CCRF-CEM, proteomics, two-dimensional protein database, mass spectrometry, MALDI-MS, 271

Thiol-proteomics, redox modification, selenium anticancer action, 25

Tissue profiling, MALDI mass spectrometry, proteomics, biomarker, soft tissue sarcoma, 333

Transcriptomics, immunoresistance, mesothelioma, microarray, lymphocyte, 125

Transitional cell carcinoma, proteomics, 151

Tumor suppressor gene, chromosome 3, FHIT, chromosome instability, mutation, FRA3B, VHL, CER1, elimination test, review, 247

Tumour promoter genes, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, review, 227

Two-dimensional protein database, human, T-cell, CCRF-CEM, proteomics, mass spectrometry, MALDI-MS, 271

VEGF, endothelial cells, adhesive properties, 265

VHL, tumor suppressor gene, chromosome 3, FHIT, chromosome instability, mutation, FRA3B, CER1, elimination test, review, 247

Zinc finger proteins, breast carcinoma, metallopanstimulin, ribosomal protein S27, 53
Authors Index
(Figures refer to page numbers)

Abou-Ghalia AH, 239
Adli A, 239
Agudo D, 145
Ahmed FE, 71, 317
Alaiya A, 347
Alrawi SJ, 307
Amaratunga AN, 353
Anagnostopoulos AK, 271
Anderson G, 307
Bailey A, 61
Baranska P, 265
Bigeard J, 199
Black AP, 61
Bottin MC, 125
Bosquet J, 199
Brooks JD, 97
Cajone F, 227
Caldwell RL, 333
Campos D, 219
Canelle L, 199
Caprioli RM, 333
Caron M, 199
Carrizales G, 219
Chen Z, 115
Choi KS, 25
Chow N-H, 151
Cierniewski CS, 265
Clynes M, 43
Datta MW, 137
Dayton M, 307
De Villareal MP, 43
Deissler H, 37
Dong Y, 97
Díaz-Gil G, 145
Döttinger A, 37
Effertih T, 115
El-Salaby E, 239
Engidawork E, 209
Fernandez-Pol JA, 1, 53
Fountoulakis M, 271
Gao AC, 97
Gibbs JF, 307
Glarner N, 83
Györffy B, 255
Gómez-Esquer F, 145
Hamilton PD, 1
Hardouin J, 199
Hawthorn L, 97
Hedenfalk I, 83
Hicks W Jr, 307
Holmberg AR, 347
Holt GE, 333
Ibrahim SO, 353
Ingvarsson S, 247
Ip C, 25, 97
Izbicka E, 219
Jacob H, 137
Jerczynska H, 265
Jones L, 61
Jouvet TQ, 37
Joubert-Caron R, 199
Kain A, 115
Kazim SK, 239
Keith G, 125
Kenny E, 43
Khoury T, 307
Kiaf A, 37
Klos DJ, 1
Kolialxi A, 271
Kong E-S, 25
Koziolekiewicz W, 265
Krohn M, 353
Kronblad A, 83
Lage H, 255
Lambe T, 61
Landberg G, 83
Liao C-F, 151
Liu H-S, 151
Liu Z, 347
Loree T, 307
Lubec G, 209
Marshall JR, 97
Martínez-Arribas F, 145
Mavrou A, 271
Micillino JC, 125
Miron T, 353
Moh R, 125
Márquez M, 347
Neuville A, 125
Nilsson S, 347
Nowak N, 97
O’Driscoll L, 43
Ogg GS, 61
Oh J-E, 209
Park E-M, 25
Park S-Y, 25
Park Y-M, 25
Pawlowksa Z, 265
Pionneau C, 199
Pollard M, 137
Pollán M, 145
Ricci L, 53
Rigual N, 307
Rihn BH, 125
Riugnér M, 83
Sait S, 307
Sauer G, 37
Schneider J, 145
Schneiderhan-Marra N, 37
Sherbet GV, 227
Shin J-H, 209
Stamatakis A, 301
Stoler D, 307
Suckow MA, 137
Sundblad AS, 53
Surowiak P, 255
Tan D, 307
Templin M, 37
Tolcher A, 219
Tonellato PJ, 137
Tsangaris GT, 271
Twigger S, 137
Vasstrand EN, 353
Veerla S, 83
Vougas K, 271
Wang G, 115
Wanakulasuriya S, 353
Wee E, 61
Wu H, 151
Wu T-F, 151
Wu Y, 25
Xynos FP, 53
Zhang H, 25, 97
Zhao H, 97
Zu K, 25
Instructions to Authors

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of application of genomic and proteomic technology to experimental and clinical cancer research. The journal's topical spectrum includes: (a) Molecular causes of carcinogenesis, cancer progression and metastasis; (b) Structural and functional aspects of genes in the cancer cell; (c) Advances in genomic and proteomic technologies applicable to cancer research; (d) Rational anticancer drug design and drug development.

CGP will also accept for publication abstracts and proceedings of scientific meetings, following consideration and approval by the Editorial Board.

The principal aim of CGP is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to CGP will be subject to review, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are treated in confidence, without access to any person other that the Editor-in-Chief, the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

Copyright. Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) Review articles concerning fields of recognizable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the 'Shorter Oxford English Dictionary'.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 2000 words, organized according to the following headings: Background - Materials and Methods - Results - Conclusions; (c) Introduction; (d) Materials and Methods, or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements, and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. A charge will be made for a colour plate.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. In the text, references should be cited by number.


CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME)" standard. Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. Research involving the use of human fetuses, fetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. An original and two copies of the manuscript (including all photographs and graphs) should be sent to: Dr. J.G. Delinassios, Managing Editor, Cancer Genomics and Proteomics, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece.

A floppy disc, CD-ROM or ZIP-disc must also be submitted indicating the computer-processing program. Authors are invited to submit along with their manuscripts a short list of possible reviewers and any previous publications which could facilitate reviewing. Manuscripts should be accompanied by six adhesive labels with the name and address of the Author to whom correspondence should be sent. Only the original copy of the submitted manuscript will be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free of charge. Additional copies may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.
CANCER GENOMICS & PROTEOMICS supports (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences please visit the IIAR website: www.iiar-anticancer.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandriotou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: 0030 22950 52945, Fax: 0030 22950 53389, e-mail (Editorial Office): journals@iiar-anticancer.org, e-mail (Managing Editor): editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook and Women's College Health Sciences Center, 2075 Bayview Avenue, Room E-423, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca


Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Managing Editor, Athens, Greece and should be sent to the Editorial Office.

Advertising: Correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.